9.930USD+0.10%Mkt Cap: —P/E: —1d ago
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of N…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value83.22M $
Revenue (TTM)—
Gross Profit-90.26M $
Net Income (TTM)-101.90M $
Revenue/Share—
Last Price9.930 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees36
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS21833P3010
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.78
EV/Revenue—
P/S—
P/B1.87
EPS (TTM)-0.31
EPS (Forward)—
52W Range
9.80214% of range10.73
52W High10.73 USD
52W Low9.802 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-95.58%
ROA-53.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-86.67M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-113.68M $
Net Debt/EBITDA1.07
Balance Sheet
Debt/Equity4.17
Current Ratio5.71
Quick Ratio5.56
Book Value/Sh5.476 USD
Cash/Share6.098 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.033333:1
Split DateFeb 14, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.57.24M
Float15.16M
Insiders0.90%
Institutions73.37%
Technical
SMA 5021.54 (-53.9%)
SMA 20010.76 (-7.7%)
Beta2.62
S&P 52W Chg20.80%
Avg Vol (30d)2.62K
Avg Vol (10d)3.92K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—